我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
8
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2011
进行中（未招募）
1
12.5%
已完成
5
62.5%
尚未招募
2
25.0%
暂无批准数据
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients. - DETOUR2 study shows percutaneous transmural arterial bypass with the DETOUR System offers durable outcomes for complex femoropopliteal lesions at three years. - The LIFE-BTK trial indicates the Global Limb Anatomic Staging System (GLASS) effectively identifies CLTI patients at higher risk for adverse events.
